2. Academic Validation
  3. Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan-Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy

Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan-Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy

  • ACS Med Chem Lett. 2025 Sep 17;16(10):1986-1996. doi: 10.1021/acsmedchemlett.5c00398.
Karanvir Singh 1,  Atamjit Singh 1,  Arprita Malhan 1,  Mridul Guleria 1,  Aanchal Khanna 1,  Aman Sharma 1,  Parth 2,  Jyoti 1,  Rahul Sharma 3,  Harbinder Singh 4,  Subheet Kumar Jain 1,  Preet Mohinder Singh Bedi 1 5
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India.
  • 2 Department of Chemistry, Ben Geurion University of Negev, Beer-sheva 8410501, Israel.
  • 3 Department of Microbiology, Guru Nanak Dev University, Amritsar, Punjab 143005, India.
  • 4 The Center for Drug Design and Development (CD3), College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio 43606, United States.
  • 5 Drug and Pollution Testing Lab, Guru Nanak Dev University, Amritsar, Punjab 143005, India.
PMID: 41089492 DOI: 10.1021/acsmedchemlett.5c00398
Abstract

A novel series of triazole-tethered monoterpenoid-lignan hybrid molecules has been designed to target Xanthine Oxidase (XO), the enzyme responsible for hyperuricemia when it is up-regulated, resulting in gout and Other metabolic disorders. Designed molecules were synthesized and initially evaluated for their XO inhibitory potential, and MT7 was most active (XO: IC50 = 0.263 ± 0.06 μM) with radical scavenging efficacy. MT7 showed higher cytotoxic potential against XO harboring Cancer cells (MBDA-MB-231 breast Cancer cells) than non-XO-harboring cells (A547 skin Cancer cells), confirming intracellular XO inhibition. MT7 was nontoxic to mouse fibroblast cells (L929) and had favorable pharmacokinetic profiles. In vivo investigations in rodent-based animal models revealed the LD50 (300 mg/kg) value of MT7 and a dose-dependent reduction in serum uric acid. Overall, this suggests MT7 as an effective lead molecule for further investigations as a potential clinical candidate for the management of hyperuricemia via XO inhibition.

Keywords

Xanthine oxidase; eugenol; hybrids; hyperuricemia; sesamol; triazole.

Figures
Products